A*Star

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

Each panel that the collaborators develop is expected to be highly multiplexed and syndromic, addressing clinically important infectious diseases in Asia.

GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.

While gain-of-function mutations lead to congenital arhinia, inactivating mutations lead to an adult-onset muscular dystrophy, the researchers reported.

The partners will collaborate in developing Atreca's single-cell sequencing technology to advance new cancer immunotherapies.

The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.

The partners will focus on sequencing and analyzing bacteria and viruses that cause a number of diseases as well as those that make up human microbiomes.

The collaboration will further develop Agilent's AssayMAP Bravo platform to bridge gaps in analytical tests and standards for glycoprotein-based drugs.